Physician profile
Michael Gedeon
NPI 1720088859
$11,441.01
in general payments reported to CMS, 2019-2025
42 companies · $877 in 2025
The $877 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,904 · 2020: $1,955 · 2021: $2,412 · 2022: $2,215 · 2023: $1,031 · 2024: $1,048 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,956.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,955.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,612.47 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,356.53 | 2019-2025 | |
| Pfizer INC. | $1,138.94 | 2019-2024 | |
| Amgen INC. | $1,011.57 | 2019-2025 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals Lp | $837.51 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $812.65 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Lilly USA, LLC | $764.51 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $594.66 | 2019-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $509.23 | 2019-2025 | Jardiance, Spiriva Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $369.61 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $304.00 | 2019-2024 | Eliquis |
| Amarin Pharma, INC. | $293.52 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $252.06 | 2019-2023 | |
| Radius Health, INC. | $171.60 | 2019-2021 | |
| Exact Sciences Corporation | $166.83 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gedeon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.